Myocardial ischaemia: new evidence for angiotensin-converting enzyme inhibition
University of Ferrara and Cardiovascular Research Center, ‘Salvatore Maugeri’ Foundation, Gussago, Brescia, Italy
1 Prof. Roberto Ferrari, Chair of Cardiology, University of Ferrara, Via Savonarola, 9, 44100 Ferrara, Italy.
Abstract
Angiotensin-converting enzyme (ACE) inhibitors undoubtedly represent a milestone in cardiovascular therapy. They are known to halt the progression of coronary artery disease by interrupting the series of events that lead to end-stage ischaemic heart disease. Moreover, in patients with severe heart failure, ACE inhibitors, quite surprisingly, reduce the recurrence of angina pectoris and myocardial infarction, hospitalization for ischaemic heart disease, and the rate of coronary artery bypass surgery or angioplasty. More recently ACE inhibitors have been postulated to reduce vascular hypertrophy, attenuate atherosclerosis and influence mortality and hospitalization when used in patients with left ventricular dysfunction without overt heart failure. The results of the Heart Outcomes Prevention Evaluation (HOPE) study confirm that this is the case, and that these agents can reduce the incidence of coronary events. Two other major trials, on the same subject but substantially different from HOPE, namely the European trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) and the Prevention of Events with ACE inhibitors (PEACE) study, are underway. The clinical hypothesis to be tested is that prolonged ACE inhibition reduces the progression of coronary atherosclerosis; the biological hypothesis is that prolonged ACE inhibition reduces or even reverses endothelial dysfunction to normal—a mechanism in which bradykinin might be significantly involved. This is the main topic of the present article.
Key Words: Acute coronary syndromes • Angina • Atherosclerosis • Myocardial infarction • Perindopril
References
- Brown NJ, Vaughan DG. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411–1420
[Abstract/Free Full Text] - Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994;23:439–449
[Abstract/Free Full Text] - Su JB, Barbe F, Crozatier B, Campbell DJ, Hittinger L. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J Cardiovasc Pharmacol. 1999;34:700–710[CrossRef][Web of Science][Medline]
- Hollenberg NK, Meggs LG, Williams GH, Katz J, Garnie JD, Harrington DP. Sodium intake and renal responses to captopril in normal man and in essential hypertesion. Kidney Int. 1981;20:240–245[Web of Science][Medline]
- Case DB, Atlas SA, Laragh JH, Sullivan PA, Sealey JE. Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response. J Cardiovasc Pharmacol. 1980;2:339–346[Web of Science][Medline]
- Candido R, Jandeleit-Dahm K, Cao Z, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation. 2002;106:246–253
[Abstract/Free Full Text] - Bartels GL, Van den Heuvel AF, Van Veldheuiusen DJ, Van der Ent M, Remme WJ. Acute anti-ischaemic effect of perindoprilat in men with coronary artery disease and their relation with left ventricular function. Am J Cardiol. 1999;83:332–336[CrossRef][Web of Science][Medline]
- Morishita T, Tsutsi M, Shimokawa H, et al. Long term treatment with perindopril ameliorated dobutamine-induced myocardial ischaemia in patients with coronary artery disease. Jpn J Pharmacol. 2002;88:100–107[CrossRef][Medline]
- The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302[Abstract]
- Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669–677[Abstract]
- CONSENSUS Trial Study Group. Effects of enalapril on mortality to severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435[Web of Science][Medline]
- Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation. 1995;92:3132–3137
[Free Full Text] - Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575–1581[CrossRef][Web of Science][Medline]
- PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction: study rationale and design. AnonymousCardiovasc Drugs Ther. 2000;14:671–679[CrossRef][Web of Science][Medline]
- The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
[Abstract/Free Full Text] - Nicolosi L, GISSI-3 Investigators. The GISII-3 echocardiographic study on the effects of lisinopril, nitrates and their combination on left ventricular remodelling in six-week survivors of acute myocardial infarction. Eur Heart J. 1994;15:327
- PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–1041[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||